Patients Aged ≥ 70 Are at High Risk for Neutropenic Infection and Should Receive Hemopoietic Growth Factors When Treated With Moderately Toxic Chemotherapy

This publication has 16 references indexed in Scilit:

• Hemopoietic Reserve in the Older Cancer Patient: Clinical and Economic Considerations
  Cancer Control, 2000
• ANTINEOPLASTIC CHEMOTHERAPY OF THE OLDER CANCER PATIENT
  Hematology/Oncology Clinics of North America, 2000
• Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma: results of a multivariate analysis.
  Journal of Clinical Oncology, 1998
• CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.
  Journal of Clinical Oncology, 1998
• Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.
  Journal of Clinical Oncology, 1997
• The Treatment of Elderly Patients with Aggressive Non-Hodgkin's Lymphomas: Feasibility and Efficacy of an Intensive Multidrug Regimen
  Leukemia & Lymphoma, 1996
• Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.
  Journal of Clinical Oncology, 1995
• Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy
  Annals of Oncology, 1994
• The Nature of Adverse Events in Hospitalized Patients
  New England Journal of Medicine, 1991
• Aggressive Chemotherapy for Diffuse Histiocytic Lymphoma in the Elderly: Increased Complications with Advancing Age
  Journal of the American Geriatrics Society, 1984